Dynavax Technologies (DVAX) Climbs On COVID-19 Vaccine Supply News

Dynavax DVAX Stock News

Dynavax Technologies Corporation (NASDAQ: DVAX) is making a run for the top in the market this morning, and for good reason. The company announced news surrounding the commercial supply of its COVID-19 vaccine candidate on a day when Gilead Sciences acquired Immunomedics, Vaxart announced FDA approval to begin human trials, and plenty of other COVID-19 vaccine stories are hitting the tape. Here’s what’s happening:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

DVAX Stock Runs For The Top On Vaccine Supply News

In the press release, Dynavax and its COVID-19 vaccine candidate partner, Valneva announced that they have entered into a commercial supply partnership surrounding the CpG 1018 adjuvant from DVAX and the SARS-CoV-2 vaccine candidate VLA2001 from Valneva.

Moreover, Valneva announced a separate agreement with the UK government to provide up to 190 million doses of VLA20011 over a five year period. Also, Dynavax will supply CpG 1018 to produce up to 100 million doses of the vaccine in 2021. Moreover, Valneva has the option to purchase up to an additional 90 million doses through 2025.

In a statement, Thomas Lingelbach, CEO at Valneva, had the following to offer:

We are pleased to partner with Dynavax on the further development and future commercialization of our COVID-19 vaccine. We believe that CpG 1018 will add significant value to the target product profile of our vaccine including its intended use in at risk populations. This agreement marks another step in our approach to find a safe and effective solution to address the virus that is continuing to have an impact on us all.

The above statement was followed up by Ryan Spencer, CEO at DVAX. Here’s what he had to offer:

Dynavax is proud to be working with Valneva to support development and commercialization of an adjuvanted vaccine candidate to prevent COVID-19. We are pleased to extend our current partnership to include commercial supply of CpG 1018, our advanced adjuvant. We believe CpG 1018 may play a critical role in the development of a safe and effective vaccine, including potentially enhancing the immune response for those who are traditionally less responsive to vaccination and are at greatest risk for severe disease from COVID-19.

This Is Huge News

The news issued by Dynavax, and its partner Valneva, is overwhelmingly positive. The companies have reached a commercial supply agreement. At the same time, the UK government has committed to purchasing up to 190 million doses from Valneva, with Valneva committing to purchase 100 million CpG 1019 adjuvant doses from DVAX, which may grow to 190 million.

What we’re seeing here is a story that surrounds tremendous revenue potential with a vaccine that could become a blockbuster. As a result, investors should keep a close eye on DVAX stock.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.